Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytokinetics (NQ: CYTK )

47.67 -2.19 (-4.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics

< Previous 1 2 3 4 5 6 7 Next >
10 Biggest Price Target Changes For Tuesday
Citigroup boosted International Business Machines Corporation (NYSE: 
Via Benzinga
54 Biggest Movers From Yesterday
Gainers Aehr Test Systems (NASDAQ: AEHR) shares climbed 87.9% to close at $6.39 on Monday after the company won a $10.8 million single purchase order from its lead silicon... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Why Is Cytokinetics Inc. (NASDAQ: CYTK) The Best Stock of the Day?
Founded in 1997, Cytokinetics Inc. focuses on muscle biology, developing muscle activators and inhibitors that improve overall function. These medications most often serve... 
Via Benzinga
Dow on Pace for Worst Day of 2021 as Covid-19 Fears Weigh
The Dow Jones Industrial Average is down more than 760 points at midday and is eyeing its worst daily drop for 2021. 
Via Talk Markets
Topics Stocks
Exposures COVID-19 US Equities
Here's Why Cytokinetics Is Rocketing Higher Today
The company's new heart drug candidate produced encouraging clinical trial results. 
Via The Motley Fool
Mid-Day Market Update: Crude Oil Dips 6%; Cytokinetics Shares Spike Higher
Midway through trading Monday, the Dow traded down 2.28% to 33,896.40 while the NASDAQ fell 1.31% to 14,238.93. The S&P also fell, dropping 1.74% to 4,251.79. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
30 Stocks Moving In Monday's Mid-Day Session
Gainers Cytokinetics, Incorporated (NASDAQ: CYTK) jumped 56.4% to $30.07 after the company disclosed topline results from Cohorts 1 and 2 of REDWOOD-HCM. Aehr Test Systems (... 
Via Benzinga
CYTK Stock Flies High on Exciting Drug Trial Results
CYTK stock is being boosted by bullish biopharma buyers today. The company is reporting with optimism regarding its newest HCM treatment. 
Via InvestorPlace
How Strong Cytokinetics Test Results Could Undermine Bristol Myers' $13.1 Billion Buyout
Cytokinetics said Monday its treatment improved blood flow for patients with a genetic heart disease, and the biotech stock sprinted. 
Via Investor's Business Daily
Mid-Morning Market Update: Markets Open Lower; AutoNation Profit Beats Estimates
Following the market opening Monday, the Dow traded down 2.31% to 33,885.81 while the NASDAQ fell 1.67% to 14,186.04. The S&P also fell, dropping 1.94% to 4,243.38. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks That Hit 52-Week Highs On Monday
On Monday morning, 20 companies achieved new highs for the year. Areas of Significance: The largest company by market cap to break to a new 52-week high was PepsiCo... 
Via Benzinga
Cytokinetics Shares Gain On Positive Data From Heart Disease Candidate
Cytokinetics Incorporated (NASDAQ: CYTK) has announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM Phase 2 trial of CK-3773274 (CK-274) in... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock moved upwards by 67.6% to $14.28 during Monday's pre-market session. The company's market cap stands at $684.2... 
Via Benzinga
Cytokinetics Post-Hoc Data Suggests Omecamtiv Mecarbil Works Better In High-Risk Patients For Heart Failure
Cytokinetics Incorporated (NASDAQ: CYTK) announced secondary data analysis from the GALACTIC-HF trial evaluating omecamtiv mecarbil in patients with heart... 
Via Benzinga
Cytokinetics Inc (CYTK) Q1 2021 Earnings Call Transcript
CYTK earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.